Indacaterol

Drug Profile

Indacaterol

Alternative Names: Arcapta Neohaler; Hirobriz Breezhaler; Indacaterol maleate; Onbrez Breezhaler; Onbrez Inhalation Capsules; Onbrize Breezhaler; Oslif Breezhaler; QAB 149

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators; Indans; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 21 Dec 2016 Indacaterol licensed to Sunovion Pharmaceuticals in USA
  • 01 Sep 2016 Novartis Pharmaceuticals plans a phase II trial for Asthma (In children, Adjunctive treatment) in European Union (Inhalation) (NCT02892019)
  • 28 Apr 2014 Efficacy data from a phase IV trial in Chronic obstructive pulmonary disease released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top